Peptide basics

CJC-1295 vs ipamorelin: what each has on the record, and what the pair has together

This page reports what exists in the trial registry, the regulatory record and the published literature for each compound. It does not describe hormonal effects, does not evaluate the pairing, and cannot support a decision about either compound.

What this comparison measures

These two compounds are named together more often than either is named alone. This page compares them on what can be counted: registered studies, the phase those studies reached, regulatory standing, publication volume, and readership.¹²⁹¹⁰

Registered human trials

In the snapshot of 1 August 2026, the registry returned one match for CJC-1295 and it was verified. For ipamorelin it returned three loose matches, of which two were confirmed to name ipamorelin as an intervention.¹²

CJC-1295's entry is NCT00267527, a phase-2 study in patients with HIV and visceral obesity, registered in 2005 and recorded as terminated. A terminated study is one that stopped early; the registry entry does not by itself say why, and a terminated trial cannot support a conclusion about the compound.³

Ipamorelin's verified entries are two phase-2 studies in postoperative gastrointestinal recovery — NCT00672074 and NCT01280344 — both recorded as completed and both placebo-controlled. Neither concerns growth-hormone release, body composition or recovery from training.⁴⁵

• CJC-1295: one registered study, phase 2, terminated.
• Ipamorelin: two registered studies, both phase 2, both completed, both in postoperative gastrointestinal function.
• Combined: three registered studies, zero of them in the indication either compound is commonly discussed for.¹²³⁴⁵

Furthest phase reached

Phase 2 is the ceiling for both. Neither compound has a registered phase-3 study, and neither has a phase-4 record, which would require an approval to exist first.¹²

Ipamorelin's ceiling is reached by completed studies and CJC-1295's by a terminated one. That is a real difference in what the phase label is standing on, and it is invisible if you compare only the highest phase reached.³⁴⁵

Regulatory status

Neither compound has an approved product. Both appear on FDA's published page for bulk drug substances nominated for use in compounding, but in different places on it, and the difference matters.⁸

Ipamorelin acetate sits in category 2 under the 503B interim policy, added 29 September 2023. FDA's stated reasons include immunogenicity risk for certain routes, the presence of unnatural amino acids complicating characterisation, and a published report of serious adverse events including death in a study of ipamorelin for gastric motility.⁸

CJC-1295 appears in the separate table of nominations later withdrawn by their nominators. FDA's entry there records serious adverse events associated with the compound, including increased heart rate and a systemic vasodilatory reaction, and states that available clinical data are limited.⁸

Publication trend, 2017 to 2026

A PubMed title/abstract search across 2017 to 2026 returns 18 records for CJC-1295 and 18 for ipamorelin. Both series sit in low single figures for most years and rise in the partial 2026 year, to 9 and 8 respectively.⁹¹⁰

The foundational human papers for each are older than this window. CJC-1295 was described in healthy adults in a 2006 endocrinology paper; ipamorelin was characterised as a selective growth hormone secretagogue in 1998. Both are cited constantly in material about these compounds, and both are single studies from the last century or the one before this decade.⁶⁷

CJC-1295's entire registered record is one terminated phase-2 study from 2005.

Ipamorelin's two completed phase-2 studies are in postoperative gastrointestinal recovery, not in growth-hormone or body-composition endpoints.

The stack has no record of its own

The two compounds are sold and discussed as a combination. In the registry snapshot, no study administers both: CJC-1295's single entry lists CJC 1295 alone, and ipamorelin's two list ipamorelin against placebo or saline.³⁴⁵

Attention against evidence

Between February and June 2026, the CJC-1295 Wikipedia article averaged 10,462 views a month and the ipamorelin article 6,559. Peaks were 11,857 and 7,938.¹²¹¹

Roughly seventeen thousand readers a month across two compounds with three registered studies between them is the pattern this site was built to make visible. Readership is a count of curiosity; it is not evidence of anything else.¹²¹¹

Common questions